Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.32 USD | +0.41% | +7.33% | +25.56% |
04-19 | TScan Therapeutics Closes $150.1 Million Securities Offering | MT |
04-17 | TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants | MT |
Sales 2024 * | 17.6M 24.06M | Sales 2025 * | 15.66M 21.41M | Capitalization | 351M 479M |
---|---|---|---|---|---|
Net income 2024 * | -103M -141M | Net income 2025 * | -119M -163M | EV / Sales 2024 * | 16 x |
Net cash position 2024 * | 68.9M 94.18M | Net cash position 2025 * | 66.72M 91.2M | EV / Sales 2025 * | 18.1 x |
P/E ratio 2024 * |
-7.12
x | P/E ratio 2025 * |
-6.48
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.66% |
1 day | +0.41% | ||
1 week | +7.33% | ||
Current month | -7.81% | ||
1 month | -8.39% | ||
3 months | +45.82% | ||
6 months | +122.49% | ||
Current year | +25.56% |
Managers | Title | Age | Since |
---|---|---|---|
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Jason Amello
DFI | Director of Finance/CFO | 55 | 01-28 |
Justin McCue
CTO | Chief Tech/Sci/R&D Officer | - | 12-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 19-02-28 | |
Stephen Biggar
BRD | Director/Board Member | 53 | 21-02-28 |
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 7.32 | +0.41% | 92,052 |
24-04-25 | 7.29 | -1.22% | 107,354 |
24-04-24 | 7.38 | +1.65% | 90,771 |
24-04-23 | 7.26 | +1.97% | 208,344 |
24-04-22 | 7.12 | +4.40% | 173,228 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.56% | 351M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TCRX Stock